房颤血清生物标记物的研究进展

心房颤动（AF）是目前临床上最常见的心律失常之一。绝大多数患者是在AF晚期已经出现无规则的心脏节律后被发现，治疗效果欠佳。近年，研究者开始关注AF早期无症状阶段的病理生理改变，发现纤维化、炎症和氧化应激等与AF密切相关，相应的生物标记物也被证明可以预示AF的发生和预后。血清生物标志物的变化是AF发生和预后的强预测因子。生物标记物作为一种廉价、安全的检测指标可以帮助临床医生对高危人群进行早期诊断、指导治疗、判断疗效和评估预后，具有较好的临床应用前景。

Advances in serum biomarkers of atrial fibrillation

Atrial fibrillation （AF） is the most common cardiac arrhythmia. The majority of patients with irregular heartbeat or abnormal heart rhythm can be diagnosed as having AF. Recent research has begun to focus on the pathophysiology of AF in asymptomatic early stages. It has been found that fibrosis, inflammation and oxidative stress are closely related to AF. The related biomarkers have been shown valu- able in predicting the occurrence and prognosis of AF. Changes in serum biomarkers are strong predictors of the occurrence and prognosis of AF. Biomarkers as an economical, non-invasive, and safe test can help clinicians identify at-risk populations. Biomarkers help in early diagnosis, disease prevention, drug target identification, and drug response.